Indian Pharma Resilient to Trump’s Generic Drug Tariff Threats

Indian pharmaceutical companies have little reason to fear former President Donald Trump’s proposed 100% tariff on imported off-patent medications by 2028, with a potential increase to 200% a year later. This policy, which demands production relocation to the United States, faces significant commercial and political obstacles.

Economic Realities of Generic Drug Production

The economics of generic drug manufacturing, characterized by high volumes and low margins, make it impractical for companies to absorb substantial tariffs or relocate production to the US. Generic medicines are fundamental to the US healthcare system, significantly lowering drug prices once branded patents expire.

• Proposed Tariff: 100% by 2028
• Potential Increase: 200% a year later
• Affected Companies: Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd.

For firms like Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd., absorbing such increased costs or moving extensive manufacturing operations to the US would be commercially unfeasible.

Broader Implications for US Healthcare

Should these tariffs be implemented, the financial burden would likely transfer to American patients and the broader healthcare system, potentially exacerbating inflation. Furthermore, certain drugs could become unprofitable to produce, leading to critical shortages which are often less acceptable than higher prices.

Such a policy would also prove politically unpopular, particularly in a presidential election year like 2028. Historically, generics manufacturing has steadily shifted out of the US over decades, with India developing unparalleled expertise and scale in this sector to become a global pharmacy.

Strategic Investments and Alternative Solutions

While some Indian pharmaceutical firms have invested in US manufacturing, these moves are strategic commercial decisions aimed at enhancing profitability for higher-margin treatments, not reactions to tariff threats. Washington’s concerns about over-reliance on overseas suppliers for essential drugs are legitimate, yet tariffs represent an inefficient approach.

More effective solutions to bolster supply chain resilience include targeted incentives for strategically vital medicines, the diversification of supply chains, and guaranteed purchasing contracts. Until the US demonstrates a genuine commitment to altering the system that has favored the cheapest and safest medicine suppliers for four decades, Indian drugmakers have minimal cause for alarm.